>Marché de la thérapie numérique (DTx) en Amérique du Nord et en Europe, par type de produit et de service (produit matériel, solutions/logiciels et service), application (applications liées au traitement/aux soins et applications préventives), mode d'achat (organisation d'achat groupé et individuel), canal de vente (B2B et B2C) - Tendances et prévisions du secteur jusqu'en 2030.
Analyse et perspectives du marché des thérapies numériques (DTx) en Amérique du Nord et en Europe
Les thérapies numériques (DTx) fournissent aux patients des thérapies fondées sur des preuves qui sont exploitées par des programmes logiciels de haute qualité pour prévenir, traiter ou soigner un trouble ou une maladie médicale. Elles sont utilisées individuellement ou en association avec des médicaments, des appareils ou d'autres remèdes pour améliorer les soins aux patients et les résultats de santé. Les produits DTx englobent les meilleures applications technologiques avancées liées à la conception, aux affirmations cliniques, à la convivialité et à la sécurité des données. Ils sont corroborés par les organismes législatifs si nécessaire pour maintenir les déclarations de produits concernant le danger, la puissance et l'utilisation délibérée. DTx fournit aux patients, aux prestataires de soins de santé et aux payeurs des outils réalisables pour enregistrer diverses conditions grâce à des médicaments protégés de haute qualité et pratiquement basés sur des données.
Certains acteurs du marché fournissent des produits et services pour les maladies chroniques, qui sont principalement utilisés par la population âgée. Au cours des dernières années, de nouveaux logiciels innovants ont vu le jour pour permettre aux gens de s'attacher davantage aux thérapies numériques pour plus de facilité. Un grand nombre d'acteurs du marché sont impliqués dans la fourniture de services pour soutenir les thérapies numériques, ce qui ouvre la voie à la croissance du marché.
Compte tenu de la diversité des produits dans l'industrie DTx, les thérapies numériques individuelles ont le potentiel de fournir aux patients, aux cliniciens et aux payeurs de nouvelles options thérapeutiques pour des besoins médicaux non satisfaits, d'être utilisées indépendamment ou en conjonction avec d'autres thérapies, d'améliorer, de soutenir ou d'optimiser les traitements médicaux actuels, de s'intégrer dans les directives médicales et les meilleures pratiques et de permettre l'expansion des soins en dehors d'un cadre clinique traditionnel.
La demande de thérapies numériques (DTx) a augmenté dans les pays développés comme dans les pays en développement, en raison de l'augmentation de la prévalence des maladies chroniques dans le monde. Le marché de la thérapie numérique (DTx) en Amérique du Nord et en Europe est en croissance en raison d'une sensibilisation accrue des organisations gouvernementales et des progrès technologiques dans le domaine des soins de santé. Le marché va croître au cours de la période de prévision avec l'adoption croissante du traitement numérique et les progrès technologiques.
Les politiques de confidentialité concernant les informations des patients, l'option de paiement numérique non acceptable et le manque d'installations Internet dans les pays sous-développés devraient freiner la croissance du marché thérapeutique numérique (DTx) en Amérique du Nord et en Europe.
North America and Europe digital therapeutic (DTx) market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that North America and Europe digital therapeutic (DTx) market will grow at a CAGR of 24.8% in North America and 23.53% in Europe during the forecast period of 2023 to 2030.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Product & Service Type (Hardware Product, Solutions/Software, and Service), Application (Treatment/ Care-Related Applications and Preventive Applications), Purchase Mode (Group Purchase Organization and Individual), Sales Channel (B2B and B2C) |
|
Countries Covered |
U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, and the Rest of Europe |
|
Market Players Covered |
Noom(U.S.), Atentiv(U.S.), Cognoa(U.S.), Kaia Health(U.S.), Ginger(U.S.), Livongo Health(U.S.), Mango Health(U.S.), Natural Cycles (Sweden), Cognifit (U.S.), Fitbit, Inc.(U.S.), Omada Health Propeller Health(U.S.), Welldoc, Inc.(U.S.), Smart Patient GMBH (Germany), Mindstrong Health(U.S.), Ayogo Health(Canada), Better Therapeutics(U.S.), 2morrow(U.S.), Canary Health(U.S.), Click Therapeutics(U.S.), Pear Therapeutics(U.S.), Voluntis(U.S.), Akili Interactive Labs(U.S.), Samsung(Korea), Resmed(U.S.), and GAIA AG(Germany) among others. |
Europe and North America Digital Therapeutic (DTx) Market Dynamics
Drivers
- Rise in the prevalence of chronic diseases
The increased prevalence of diseases such as diabetes, hypertension, and asthma, among others, led to the rising demand for digital therapeutic products. People want to get affordable and comfortable treatment options quickly and in the easiest way. Digital Therapeutic is one such platform offering these services very easily and user friendly. With the rising prevalence of chronic diseases and increased demand for digital therapeutics, this platform serves well for patients. The advancement is required, and digital therapeutic provide such services, which would help in the growth of the North America and Europe digital therapeutic (DTx) market.
The prevalence of the chronic disease is the strongest driving factor in the market. Hence, this instance is expected to act as a driver in the growth of the market.
- Increase In Awareness By Government Agencies
The growing awareness among the providers, payers and employers about the different advantages that these products/services provide, as well as the healthcare cost, helps drive the market growth. The Digital Health Center of Excellence (DHCoE), part of the organized growth of the Digital Health Program in the Center for Devices and Radiological Health (CDRH), had lined up and harmonized with the digital health work beyond the FDA. It had noticed the beginning of a broad approach to digital health technology, setting the phase for promoting and grasping the possibility of digital health.
The Digital Medicine Society (DiMe) is the pioneer professional corporation for a specialist from all authorities containing the various province of digital medicine. DiMe subsists to facilitate digital medicine to develop human health. The purposes they offer are communication & education, research and building community. These strategies is expected to act as a driver in the market growth.
Opportunities
- Rising demand for digital therapeutics
The demand for digital therapeutics is rising as they give the following things: physical and mental goodness, avoidance, personal care, divided care and shared decision making, long term condition handling, and correct utilization of urgent and emergency care.
Digital therapeutics provide access to the optimal level of healthcare services, innovative solutions across all levels, affordable healthcare solutions for payer, payee and society, quality of healthcare delivery and solution outcomes can be seen, patient-centricity, personalization for both patient and staff satisfaction, and also provide faster diagnosis and action based upon data given and prevention through education, information, empowerment, alert systems. Thus, the rising demand for digital therapeutics is expected to act as an opportunity in the market's growth.
Restraints
- Patient Information Privacy Policies
Privacy is the main hurdle for digital therapeutics. People are more interested in getting treatment via traditional healthcare providers. These apps require certain personal information that the patients do not want to disclose and want to keep secret. Thus certain privacy factors would hinder the growth of the market.
Moreover, personal health information is no longer private such apps take the information without concern and share it with third parties, like in social media for advertising.
Hence, the privacy concerns related to digital therapeutics apps is expected to act as a restraint to the growth of the market
Challenges
- Clinical Validation
Companies need to get clinical validation before promoting their product in the market. In some cases, they would require approval from the FDA. These procedures take a long time and sometimes don't show positive results.
Since these clinical studies related to digital therapeutics take time to finish, this is expected to act as a challenge for the market.
North America and Europe Digital Therapeutic (DTx) Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Digital Therapeutic (DTx) Market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you take an informed market decision to achieve market growth.
Recent Development
- In January 2023, Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced the inclusion of its PDTs reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List (PDL). reSET and reSET-O, the only FDA-authorized PDTs for the treatment of substance use disorder and opioid use disorder, respectively, have been added to the Florida Medicaid PDL, effective January 1, 2023
- In December 2022, Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, announced that it had received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for CT-132. Click’s CT-132 prescription digital therapeutic is under development as an adjunctive preventive treatment for episodic migraine in patients aged 18 years and older
Europe and North America Digital Therapeutic (DTx) Market Segmentation
North America and Europe digital therapeutic (DTx) market is categorized into four momentous segments, which are based on product and service type, application, purchase mode and sales channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Product and Service Type
- HARDWARE PRODUCTS
- SOLUTIONS/ SOFTWARE
- SERVICE
On the basis of product and service type, North America and Europe digital therapeutic (DTx) market is segmented into hardware products, solutions/software and service.
BY APPLICATION
- TREATMENT/CARE-RELATED APPLICATIONS
- PREVENTIVE APPLICATIONS
On the basis of application, North America and Europe digital therapeutic (DTx) market is segmented into treatment/ care-related applications and preventive applications.
BY PURCHASE MODE
- GROUP PURCHASE ORGANIZATION
- INDIVIDUAL
On the basis of purchase mode, North America and Europe digital therapeutic (DTx) market is segmented into group purchase organization and individual.
BY SALES CHANNEL
- B2B
- B2C
On the basis of sales channel, North America and Europe digital therapeutic (DTx) market is segmented into B2B and B2C.
Analyse/perspectives régionales du marché des thérapies numériques (DTx)
Le marché thérapeutique numérique (DTx) est analysé et des informations et tendances sur la taille du marché sont fournies par pays, type de produit et de service, application, mode d'achat et canal de vente.
Le marché thérapeutique numérique (DTx) comprend les États-Unis, le Canada, le Mexique, l'Allemagne, le Royaume-Uni, la France, l'Italie, l'Espagne, les Pays-Bas, la Russie, la Suisse, la Turquie, la Belgique et le reste de l'Europe.
L’Amérique du Nord devrait dominer le marché de la thérapie numérique (DTx) en raison de la sensibilisation croissante des consommateurs aux bienfaits des microalgues pour la santé et de l’augmentation de la demande de produits à base de microalgues.
La section pays du rapport fournit également des facteurs individuels d'impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. L'analyse des points de données en aval et en amont de la chaîne de valeur, l'analyse des tendances techniques des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques nord-américaines et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des soins à domicile
Le paysage concurrentiel du marché de la thérapie numérique (DTx) en Amérique du Nord et en Europe fournit des détails par concurrents. Les détails inclus sont un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'accent mis par les entreprises sur le marché hérité de la thérapie numérique (DTx) en Amérique du Nord et en Europe.
Certains des principaux acteurs opérant sur le marché thérapeutique numérique (DTx) en Amérique du Nord et en Europe sont : SAMSUNG, Voluntis, Livongo, Fitbit, Inc., ResMed, Natural Cycles USA Corp, GAIA AG, Smartpatient gmbh, Kaia Health, Pear Therapeutics Inc. entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT AND SERVICE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, INDUSTRY INSIGHT
CONCLUSION: 53
6 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, REGULATION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES
7.1.2 INCREASE IN AWARENESS BY GOVERNMENT AGENCIES
7.1.3 TECHNOLOGICAL ADVANCEMENT IN HEALTHCARE
7.1.4 INCREASED NUMBER OF PEOPLE USING SMARTPHONES
7.1.5 IMPROVED QUALITY OF LIFE
7.2 RESTRAINTS
7.2.1 PATIENT INFORMATION PRIVACY POLICIES
7.2.2 DIGITAL PAYMENT ASSOCIATED WITH DIGITAL THERAPEUTICS
7.2.3 UNDERDEVELOPED COUNTRIES LACKING SMARTPHONES AND INTERNET FACILITIES
7.3 OPPORTUNITIES
7.3.1 RISING DEMAND FOR DIGITAL THERAPEUTICS
7.3.2 COLLABORATION BETWEEN COMPANIES TO PROVIDE BETTER PRODUCTS/SERVICES
7.3.3 PARTNERSHIP BETWEEN COMPANIES
7.3.4 EXPANSION AND LAUNCH OF PRODUCTS
7.3.5 EVENTS AND EXHIBITION
7.3.6 PHYSICIAN ADOPTION
7.4 CHALLENGES
7.4.1 CLINICAL VALIDATION
7.4.2 REGULATORY APPROVAL
7.4.3 PAYER REIMBURSEMENT
8 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE
8.1 OVERVIEW
8.2 SOLUTIONS/SOFTWARE
8.3 HARDWARE PRODUCTS
8.4 SERVICE
9 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 TREATMENT/CARE-RELATED APPLICATIONS
9.2.1 DIABETIS
9.2.1.1 TYPE 2
9.2.1.2 TYPE 1
9.2.2 CENTRAL NERVOUS SYSTEM DISORDERS
9.2.2.1 MENTAL HEALTH DISORDER
9.2.2.2 OTHER CNS DISORDERS
9.2.3 SMOKING CESSATION
9.2.4 CHRONIC RESPIRATORY DISEASES
9.2.4.1 ASTHMA
9.2.4.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE
9.2.4.3 OTHERS
9.2.5 CARDIOVASCULAR DISEASES
9.2.5.1 ARRHYTMIA
9.2.5.2 HEART FAILURE
9.2.5.3 OTHERS
9.2.6 MEDICATION ADHERENCE
9.2.7 ONCOLOGY
9.2.8 GASTROINTESTINAL DISORDERS
9.2.9 REHABILITATION & PATIENT CARE
9.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT
9.2.11 OTHER TREATMENT/CARE-RELATED APPLICATIONS
9.3 PREVENTIVE APPLICATION
9.3.1 HEART ATTACKS
9.3.2 PREDIABETES
9.3.3 OBESITY
9.3.4 NUTRITION
9.3.5 LIFESTYLE MANAGEMENT
9.3.6 OTHER PREVENTIVE APPLICATIONS
10 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE
10.1 OVERVIEW
10.2 GROUP PURCHASE ORGANIZATION
10.3 SOLUTIONS/SOFTWARE
10.4 HARDWARE PRODUCTS
10.5 SERVICE
10.6 INDIVIDUAL
10.6.1 SOLUTIONS/SOFTWARE
10.6.2 HARDWARE PRODUCTS
10.6.3 SERVICE
11 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL
11.1 OVERVIEW
11.2 B2B
11.2.1 PAYERS
11.2.2 EMPLOYERS
11.2.3 PHARMACEUTICAL COMPANIES
11.2.4 PROVIDERS
11.2.5 OTHER BUYERS
11.3 B2C
11.3.1 CAREGIVERS
11.3.2 PATIENTS
12 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
12.2 EUROPE
12.2.1 GERMANY
12.2.2 FRANCE
12.2.3 ITALY
12.2.4 U.K.
12.2.5 SPAIN
12.2.6 SWITZERLAND
12.2.7 IRELAND
12.2.8 NETHERLANDS
12.2.9 RUSSIA
12.2.10 HUNGARY
12.2.11 TURKEY
12.2.12 AUSTRIA
12.2.13 POLAND
12.2.14 NORWAY
12.2.15 LITHUANIA
12.2.16 REST OF EUROPE
13 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13.2 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 SAMSUNG
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 VOLUNTIS
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 NOOM, INC.
15.3.1 COMPANY SNAPSHOT
15.3.2 PRODUCT PORTFOLIO
15.3.3 RECENT DEVELOPMENT
15.4 FITBIT, INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 PRODUCT PORTFOLIO
15.4.3 RECENT DEVELOPMENTS
15.5 LIVONGO
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 AKILI INTERACTIVE LABS, INC.
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.7 ATENTIV
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 AYOGO HEALTH INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BETTER THERAPEUTICS, INC
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENTS
15.1 CANARY HEALTH
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 COGNOA
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 COGNIFIT
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 CLICK THERAPEUTICS, INC.
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 GINGER
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 GAIA AG
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 KAIA HEALTH
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENTS
15.17 MANGO HEALTH
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 MINDSTRONG HEALTH
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 2MORROW INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENTS
15.2 NATURAL CYCLES USA CORP
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.21 OMADA HEALTH, INC.
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENTS
15.22 PEAR THERAPEUTICS, INC.
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENT
15.23 RESMED
15.23.1 COMPANY SNAPSHOT
15.23.2 REVENUE ANALYSIS
15.23.3 PRODUCT PORTFOLIO
15.23.4 RECENT DEVELOPMENT
15.24 SMARTPATIENT GMBH
15.24.1 COMPANY SNAPSHOT
15.24.2 PRODUCT PORTFOLIO
15.24.3 RECENT DEVELOPMENT
15.25 WELLDOC, INC.
15.25.1 COMPANY SNAPSHOT
15.25.2 PRODUCT PORTFOLIO
15.25.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
Liste des tableaux
TABLE 1 REGULATORY FRAMEWORK
TABLE 2 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 4 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 6 EUROPE TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 8 EUROPE DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 22 EUROPE INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 24 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 26 EUROPE B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 28 EUROPE B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 31 U.S. DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 32 U.S. DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 33 U.S. TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 34 U.S. CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 35 U.S. CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 36 U.S. CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 37 U.S. DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 38 U.S. PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 39 U.S. DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 40 U.S. GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 41 U.S. INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 42 U.S. DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 43 U.S. B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 44 U.S. B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 45 CANADA DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 46 CANADA DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 47 CANADA TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 48 CANADA CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 49 CANADA CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 50 CANADA CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 51 CANADA DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 52 CANADA PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 53 CANADA DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 54 CANADA GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 55 CANADA INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 56 CANADA DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 57 CANADA B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 58 CANADA B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 59 MEXICO DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 60 MEXICO DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 61 MEXICO TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 62 MEXICO CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 63 MEXICO CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 64 MEXICO CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 65 MEXICO DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 66 MEXICO PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 67 MEXICO DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 68 MEXICO GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 69 MEXICO INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 70 MEXICO DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 71 MEXICO B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 72 MEXICO B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 73 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 74 GERMANY DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 75 GERMANY DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 76 GERMANY TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 77 GERMANY CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 78 GERMANY CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 GERMANY CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 GERMANY DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 81 GERMANY PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 82 GERMANY DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 83 GERMANY GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 84 GERMANY INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 85 GERMANY DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 86 GERMANY B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 87 GERMANY B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 88 FRANCE DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 89 FRANCE DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 90 FRANCE TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 91 FRANCE CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 92 FRANCE CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 93 FRANCE CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 94 FRANCE DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 95 FRANCE PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 96 FRANCE DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 97 FRANCE GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 98 FRANCE INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 99 FRANCE DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 100 FRANCE B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 101 FRANCE B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 102 ITALY DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 103 ITALY DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 104 ITALY TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 105 ITALY CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 106 ITALY CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 107 ITALY CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 ITALY DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 ITALY PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 110 ITALY DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 111 ITALY GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 112 ITALY INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 113 ITALY DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 114 ITALY B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 115 ITALY B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 116 U.K. DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 117 U.K. DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 118 U.K. TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 119 U.K. CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 120 U.K. CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 121 U.K. CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 122 U.K. DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 123 U.K. PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 124 U.K. DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 125 U.K. GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 126 U.K. INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 127 U.K. DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 128 U.K. B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 129 U.K. B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 130 SPAIN DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 131 SPAIN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 132 SPAIN TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 133 SPAIN CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 134 SPAIN CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 135 SPAIN CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 136 SPAIN DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 137 SPAIN PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 SPAIN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 139 SPAIN GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 140 SPAIN INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 141 SPAIN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 142 SPAIN B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 143 SPAIN B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 144 SWITZERLAND DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 145 SWITZERLAND DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 146 SWITZERLAND TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 147 SWITZERLAND CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 148 SWITZERLAND CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 149 SWITZERLAND CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 150 SWITZERLAND DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 151 SWITZERLAND PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 152 SWITZERLAND DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 153 SWITZERLAND GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 154 SWITZERLAND INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 155 SWITZERLAND DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 156 SWITZERLAND B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 157 SWITZERLAND B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 158 IRELAND DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 159 IRELAND DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 160 IRELAND TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 161 IRELAND CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 162 IRELAND CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 163 IRELAND CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 164 IRELAND DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 165 IRELAND PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 166 IRELAND DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 167 IRELAND GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 168 IRELAND INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 169 IRELAND DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 170 IRELAND B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 171 IRELAND B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 172 NETHERLANDS DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 173 NETHERLANDS DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 174 NETHERLANDS TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 175 NETHERLANDS CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 176 NETHERLANDS CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 177 NETHERLANDS CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 178 NETHERLANDS DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 179 NETHERLANDS PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 180 NETHERLANDS DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 181 NETHERLANDS GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 182 NETHERLANDS INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 183 NETHERLANDS DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 184 NETHERLANDS B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 185 NETHERLANDS B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 186 RUSSIA DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 187 RUSSIA DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 188 RUSSIA TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 189 RUSSIA CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 190 RUSSIA CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 191 RUSSIA CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 192 RUSSIA DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 193 RUSSIA PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 194 RUSSIA DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 195 RUSSIA GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 196 RUSSIA INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 197 RUSSIA DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 198 RUSSIA B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 199 RUSSIA B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 200 HUNGARY DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 201 HUNGARY DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 202 HUNGARY TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 203 HUNGARY CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 204 HUNGARY CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 205 HUNGARY CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 206 HUNGARY DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 207 HUNGARY PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 208 HUNGARY DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 209 HUNGARY GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 210 HUNGARY INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 211 HUNGARY DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 212 HUNGARY B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 213 HUNGARY B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 214 TURKEY DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 215 TURKEY TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 216 TURKEY TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 217 TURKEY CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 218 TURKEY CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 219 TURKEY CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 220 TURKEY DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 221 TURKEY PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 222 TURKEY DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 223 TURKEY GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 224 TURKEY INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 225 TURKEY DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 226 TURKEY B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 227 TURKEY B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 228 AUSTRIA DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 229 AUSTRIA DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 230 AUSTRIA TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 231 AUSTRIA CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 232 AUSTRIA CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 233 AUSTRIA CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 234 AUSTRIA DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 235 AUSTRIA PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 236 AUSTRIA DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 237 AUSTRIA GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 238 AUSTRIA INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 239 AUSTRIA DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 240 AUSTRIA B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 241 AUSTRIA B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 242 POLAND DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 243 POLAND DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 244 POLAND TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 245 POLAND CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 246 POLAND CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 247 POLAND CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 248 POLAND DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 249 POLAND PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 250 POLAND DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 251 POLAND GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 252 POLAND INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 253 POLAND DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 254 POLAND B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 255 POLAND B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 256 NORWAY DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 257 NORWAY DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 258 NORWAY TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 259 NORWAY CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 260 NORWAY CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 261 NORWAY CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 262 NORWAY DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 263 NORWAY PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 264 NORWAY DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 265 NORWAY GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 266 NORWAY INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 267 NORWAY DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 268 NORWAY B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 269 NORWAY B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 270 LITHUANIA DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
TABLE 271 LITHUANIA DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 272 LITHUANIA TREATMENT/CARE-RELATED APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 273 LITHUANIA CENTRAL NERVOUS SYSTEM DISORDERS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 274 LITHUANIA CARDIOVASCULAR DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 275 LITHUANIA CHRONIC RESPIRATORY DISEASES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 276 LITHUANIA DIABETES IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 277 LITHUANIA PREVENTIVE APPLICATIONS IN DIGITAL THERAPEUTIC (DTX) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 278 LITHUANIA DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 279 LITHUANIA GROUP PURCHASE ORGANIZATION IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 280 LITHUANIA INDIVIDUAL IN DIGITAL THERAPEUTIC (DTX) MARKET, BY PURCHASE MODE, 2021-2030 (USD MILLION)
TABLE 281 LITHUANIA DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 282 LITHUANIA B2B IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 283 LITHUANIA B2C IN DIGITAL THERAPEUTIC (DTX) MARKET, BY SALES CHANNEL, 2021-2030 (USD MILLION)
TABLE 284 REST OF EUROPE DIGITAL THERAPEUTIC (DTX) MARKET, BY PRODUCT AND SERVICE TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: SEGMENTATION
FIGURE 2 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: DROC ANALYSIS
FIGURE 4 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 10 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: SEGMENTATION
FIGURE 12 THE INCREASING DEMAND FOR DIGITAL THERAPEUTICS IS INCREASING WORLDWIDE DUE TO THE PREVALENCE OF CHRONIC DISEASES IS EXPECTED TO DRIVE THE MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030.
FIGURE 13 SOLUTIONS/ SOFTWARES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET IN 2023 & 2030
FIGURE 14 SOLUTIONS/ SOFTWARES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DIGITAL THERAPEUTIC (DTX) MARKET IN 2023 & 2030
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE AND NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET
FIGURE 16 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY PRODUCT AND SERVICE TYPE, 2022
FIGURE 17 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY PRODUCT AND SERVICE TYPE, 2023-2030 (USD MILLION)
FIGURE 18 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY PRODUCT AND SERVICE TYPE, CAGR (2023-2030)
FIGURE 19 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY PRODUCT AND SERVICE TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY PRODUCT AND SERVICE TYPE, 2022
FIGURE 21 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY PRODUCT AND SERVICE TYPE, 2023-2030 (USD MILLION)
FIGURE 22 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY PRODUCT AND SERVICE TYPE, CAGR (2023-2030)
FIGURE 23 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY PRODUCT AND SERVICE TYPE, LIFELINE CURVE
FIGURE 24 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY APPLICATION, 2022
FIGURE 25 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 26 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 27 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 28 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY APPLICATION, 2022
FIGURE 29 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 30 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 31 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 32 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY PURCHASE MODE, 2022
FIGURE 33 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY PURCHASE MODE, 2023-2030 (USD MILLION)
FIGURE 34 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY PURCHASE MODE, CAGR (2023-2030)
FIGURE 35 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY PURCHASE MODE, LIFELINE CURVE
FIGURE 36 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY PURCHASE MODE, 2022
FIGURE 37 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY PURCHASE MODE, 2023-2030 (USD MILLION)
FIGURE 38 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY PURCHASE MODE, CAGR (2023-2030)
FIGURE 39 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY PURCHASE MODE, LIFELINE CURVE
FIGURE 40 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY SALES CHANNEL, 2022
FIGURE 41 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY SALES CHANNEL, 2023-2030 (USD MILLION)
FIGURE 42 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY SALES CHANNEL, CAGR (2023-2030)
FIGURE 43 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY SALES CHANNEL, LIFELINE CURVE
FIGURE 44 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY SALES CHANNEL, 2022
FIGURE 45 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY SALES CHANNEL, 2023-2030 (USD MILLION)
FIGURE 46 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY SALES CHANNEL, CAGR (2023-2030)
FIGURE 47 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY SALES CHANNEL, LIFELINE CURVE
FIGURE 48 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: SNAPSHOT (2022)
FIGURE 49 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY COUNTRY (2022)
FIGURE 50 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY COUNTRY (2023 & 2030)
FIGURE 51 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: BY COUNTRY (2022 & 2030)
FIGURE 52 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: PRODUCT AND SERVICE TYPE (2023-2030)
FIGURE 53 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: SNAPSHOT (2022)
FIGURE 54 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY COUNTRY (2022)
FIGURE 55 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY COUNTRY (2023 & 2030)
FIGURE 56 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: BY COUNTRY (2022 & 2030)
FIGURE 57 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: PRODUCT AND SERVICE TYPE (2023-2030)
FIGURE 58 NORTH AMERICA DIGITAL THERAPEUTIC (DTX) MARKET: COMPANY SHARE 2022 (%)
FIGURE 59 EUROPE DIGITAL THERAPEUTIC (DTX) MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
